EnClear Therapies, Inc.
65 Parker Street #3A. Newburyport, MA 01950

©2018 by EnClear Therapies. Proudly created with Wix.com

About EnClear

EnClear Therapies was conceived with the sole purpose of developing novel device-based therapies to treat patients with neurodegenerative disease. The companies first products will aim to halt the progression of ALS and PSP.

At EnClear Therapies, leading scientific and clinical minds in the field of neurodegenerative disease have come together with experts in medical device design to bring new therapies to patients who currently have no other options for treatment.​

The EnClear Team


Scientific Adviser, Co-Founder

Kevin Eggan, Ph.D.

  • Professor in the Department of Stem Cell and Regenerative Biology, Harvard University

  • Director, Stem Cell Biology, The Broad Institute

Scientific Advisory Board

Kevin Eggan, Ph.D.

Professor of Stem Cell and Regenerative Biology at Harvard University

Clifford Woolf, Ph.D.

Director FM Kirby Neurobiology Center at Children's Hospital Boston

Manuel Navia, Ph.D.

Founder & President, Hub-Bio Strategic Advising

Bernhardt Trout, Ph.D.

Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering, MIT and Member of the Advisory Board at Hedgeness

Clinical Advisory Board

William Brian Gormley, MD, MPH, MBA

Director. Neurosurgical Critical Care, BWH

Assistant Professor of Surgery. Harvard Medical School

Josh Vose, MD, MBA

Medical Director, Medical and Clinical Affairs Professional, Physician and Engineer

Board Of Directors

Jonathan Fleming, M.P.A.


Anthony R. DePasqua

President & CEO

EnClear Therapies

Hillel Bachrach

Managing Partner

20/20 HealthCare Partners

Jason Camm

Managing Director & Chief Medical Officer

Thiel Capital

Kasper Roet, Ph.D.

President & CEO


Gladys Nunez (Observer)


Amgen Ventures at Amgen